Caredx announces presentation of data at 2025 tandem meetings demonstrating strong performance of alloheme in early relapse detection for hematologic malignancies

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna) – the transplant company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new alloheme data presented at the 2025 tandem meetings, transplantation & cellular therapy meetings of astct™ and cibmtr®, held february 12-15, 2025 in honolulu, hawaii. in an oral prese.
CDNA Ratings Summary
CDNA Quant Ranking